American Bio Medica Corporation (ABMC)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -1.41 Million USD | -204.54% |
| 2021 | -463 Thousand USD | 41.83% |
| 2020 | -796 Thousand USD | -16.89% |
| 2019 | -681 Thousand USD | 33.75% |
| 2018 | -1.02 Million USD | -88.62% |
| 2017 | -545 Thousand USD | -57.97% |
| 2016 | -345 Thousand USD | -3.6% |
| 2015 | -333 Thousand USD | 32.04% |
| 2014 | -490 Thousand USD | 37.82% |
| 2013 | -788 Thousand USD | 29.07% |
| 2012 | -1.11 Million USD | -222.03% |
| 2011 | -345 Thousand USD | 54.0% |
| 2010 | -750 Thousand USD | 16.67% |
| 2009 | -900 Thousand USD | -5.88% |
| 2008 | -850 Thousand USD | 14.14% |
| 2007 | -990 Thousand USD | -605.1% |
| 2006 | 196 Thousand USD | 152.13% |
| 2005 | -376 Thousand USD | -241.35% |
| 2004 | 266 Thousand USD | -74.2% |
| 2003 | 1.03 Million USD | 43.39% |
| 2002 | 719 Thousand USD | 0.0% |
| 2001 | - USD | 100.0% |
| 2000 | -2.13 Million USD | -26.32% |
| 1999 | -1.69 Million USD | 61.57% |
| 1998 | -4.4 Million USD | -770.73% |
| 1997 | -505.32 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q2 | - USD | -100.0% |
| 2023 Q1 | 3.95 Million USD | 1339.18% |
| 2023 Q3 | - USD | 0.0% |
| 2022 Q2 | -400 Thousand USD | 6.32% |
| 2022 Q1 | -427 Thousand USD | -0.47% |
| 2022 FY | -1.41 Million USD | -204.54% |
| 2022 Q4 | -319 Thousand USD | 12.84% |
| 2022 Q3 | -366 Thousand USD | 8.5% |
| 2021 Q4 | -425 Thousand USD | -164.1% |
| 2021 FY | -463 Thousand USD | 41.83% |
| 2021 Q1 | -556 Thousand USD | -138.63% |
| 2021 Q2 | -245 Thousand USD | 55.94% |
| 2021 Q3 | 663 Thousand USD | 370.61% |
| 2020 FY | -796 Thousand USD | -16.89% |
| 2020 Q2 | -21 Thousand USD | 93.54% |
| 2020 Q3 | -216 Thousand USD | -928.57% |
| 2020 Q1 | -325 Thousand USD | -35.42% |
| 2020 Q4 | -233 Thousand USD | -7.87% |
| 2019 Q1 | -240 Thousand USD | 41.89% |
| 2019 Q2 | -56 Thousand USD | 76.67% |
| 2019 Q3 | -144 Thousand USD | -157.14% |
| 2019 Q4 | -240 Thousand USD | -66.67% |
| 2019 FY | -681 Thousand USD | 33.75% |
| 2018 FY | -1.02 Million USD | -88.62% |
| 2018 Q4 | -413 Thousand USD | -104.46% |
| 2018 Q3 | -202 Thousand USD | -37.41% |
| 2018 Q1 | -267 Thousand USD | 8.87% |
| 2018 Q2 | -147 Thousand USD | 44.94% |
| 2017 Q1 | -132 Thousand USD | 38.6% |
| 2017 Q3 | -49 Thousand USD | 30.99% |
| 2017 Q4 | -293 Thousand USD | -497.96% |
| 2017 FY | -545 Thousand USD | -57.97% |
| 2017 Q2 | -71 Thousand USD | 46.21% |
| 2016 Q4 | -215 Thousand USD | -144.32% |
| 2016 FY | -345 Thousand USD | -3.6% |
| 2016 Q1 | 1000.00 USD | 100.49% |
| 2016 Q2 | -44 Thousand USD | -4500.0% |
| 2016 Q3 | -88 Thousand USD | -100.0% |
| 2015 Q4 | -203 Thousand USD | -10050.0% |
| 2015 Q2 | -83 Thousand USD | -84.44% |
| 2015 Q3 | -2000.00 USD | 97.59% |
| 2015 FY | -333 Thousand USD | 32.04% |
| 2015 Q1 | -45 Thousand USD | 81.09% |
| 2014 FY | -490 Thousand USD | 37.82% |
| 2014 Q1 | 9000.00 USD | -93.79% |
| 2014 Q2 | -41 Thousand USD | -555.56% |
| 2014 Q4 | -238 Thousand USD | -12.8% |
| 2014 Q3 | -211 Thousand USD | -414.63% |
| 2013 Q3 | -213 Thousand USD | 27.55% |
| 2013 Q4 | 145 Thousand USD | 168.08% |
| 2013 FY | -788 Thousand USD | 29.07% |
| 2013 Q2 | -294 Thousand USD | 30.66% |
| 2013 Q1 | -424 Thousand USD | 24.96% |
| 2012 Q4 | -565 Thousand USD | -114.02% |
| 2012 Q3 | -264 Thousand USD | -242.86% |
| 2012 Q2 | -77 Thousand USD | 62.62% |
| 2012 Q1 | -206 Thousand USD | -1273.33% |
| 2012 FY | -1.11 Million USD | -222.03% |
| 2011 Q1 | -425 Thousand USD | -24.27% |
| 2011 FY | -345 Thousand USD | 54.0% |
| 2011 Q3 | -28 Thousand USD | -122.76% |
| 2011 Q4 | -15 Thousand USD | 46.43% |
| 2011 Q2 | 123 Thousand USD | 128.94% |
| 2010 Q2 | 167 Thousand USD | 160.51% |
| 2010 FY | -750 Thousand USD | 16.67% |
| 2010 Q4 | -342 Thousand USD | -14.0% |
| 2010 Q3 | -300 Thousand USD | -279.64% |
| 2010 Q1 | -276 Thousand USD | -46.81% |
| 2009 Q3 | -241 Thousand USD | -10.05% |
| 2009 FY | -900 Thousand USD | -5.88% |
| 2009 Q1 | -252 Thousand USD | 62.56% |
| 2009 Q2 | -219 Thousand USD | 13.1% |
| 2009 Q4 | -188 Thousand USD | 21.99% |
| 2008 Q1 | -199 Thousand USD | -610.71% |
| 2008 FY | -850 Thousand USD | 14.14% |
| 2008 Q2 | -64 Thousand USD | 67.84% |
| 2008 Q4 | -673 Thousand USD | -882.56% |
| 2008 Q3 | 86 Thousand USD | 234.38% |
| 2007 Q3 | -252 Thousand USD | 38.98% |
| 2007 Q4 | -28 Thousand USD | 88.89% |
| 2007 FY | -990 Thousand USD | -605.1% |
| 2007 Q1 | -297 Thousand USD | -385.58% |
| 2007 Q2 | -413 Thousand USD | -39.06% |
| 2006 FY | 196 Thousand USD | 152.13% |
| 2006 Q1 | 11 Thousand USD | 101.23% |
| 2006 Q2 | 97 Thousand USD | 781.82% |
| 2006 Q3 | -16 Thousand USD | -116.49% |
| 2006 Q4 | 104 Thousand USD | 750.0% |
| 2005 Q3 | 298 Thousand USD | 101.35% |
| 2005 Q4 | -896 Thousand USD | -400.67% |
| 2005 Q2 | 148 Thousand USD | 100.0% |
| 2005 Q1 | 74 Thousand USD | 207.25% |
| 2005 FY | -376 Thousand USD | -241.35% |
| 2004 Q1 | 24 Thousand USD | -72.73% |
| 2004 Q4 | -69 Thousand USD | -124.82% |
| 2004 Q2 | 33 Thousand USD | 37.5% |
| 2004 Q3 | 278 Thousand USD | 742.42% |
| 2004 FY | 266 Thousand USD | -74.2% |
| 2003 Q2 | 424 Thousand USD | 6157.14% |
| 2003 Q1 | -7000.00 USD | 72.0% |
| 2003 Q4 | 88 Thousand USD | -83.27% |
| 2003 Q3 | 526 Thousand USD | 24.06% |
| 2003 FY | 1.03 Million USD | 43.39% |
| 2002 FY | 719 Thousand USD | 0.0% |
| 2002 Q1 | 54 Thousand USD | 0.0% |
| 2002 Q2 | 252 Thousand USD | 366.67% |
| 2002 Q3 | 438 Thousand USD | 73.81% |
| 2002 Q4 | -25 Thousand USD | -105.71% |
| 2001 FY | - USD | 100.0% |
| 2001 Q3 | -559 Thousand USD | -163.68% |
| 2001 Q2 | -212 Thousand USD | 56.82% |
| 2001 Q1 | -491 Thousand USD | 5.94% |
| 2000 Q2 | -273 Thousand USD | 83.77% |
| 2000 FY | -2.13 Million USD | -26.32% |
| 2000 Q3 | -594 Thousand USD | -117.58% |
| 2000 Q1 | -1.68 Million USD | -323.68% |
| 2000 Q4 | -522 Thousand USD | 12.12% |
| 1999 Q2 | -27 Thousand USD | 96.84% |
| 1999 Q3 | -30 Thousand USD | -11.11% |
| 1999 FY | -1.69 Million USD | 61.57% |
| 1999 Q4 | -397 Thousand USD | -1223.33% |
| 1999 Q1 | -855 Thousand USD | -50.79% |
| 1998 Q3 | 9000.00 USD | 103.26% |
| 1998 Q4 | -567 Thousand USD | -6400.0% |
| 1998 FY | -4.4 Million USD | -770.73% |
| 1998 Q1 | -3.8 Million USD | -442.86% |
| 1998 Q2 | -276 Thousand USD | 92.74% |
| 1997 Q4 | -700 Thousand USD | 0.0% |
| 1997 FY | -505.32 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Arrayit Corporation | -3.31 Million USD | 57.474% |
| Atlantic International Corp. | -5.62 Million USD | 74.945% |
| Biocept, Inc. | -32.08 Million USD | 95.606% |
| Bioqual, Inc. | 483.48 Thousand USD | 391.635% |
| CardioGenics Holdings Inc | -1.91 Million USD | 26.422% |
| DermTech, Inc. | -100.88 Million USD | 98.602% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.02 Billion USD | 100.07% |
| HTG Molecular Diagnostics, Inc. | -21.59 Million USD | 93.471% |
| iMD Companies, Inc. | -200.63 Thousand USD | -602.765% |
| IDenta Corp. | 14.64 Thousand USD | 9728.517% |
| Interpace Biosciences, Inc. | 802 Thousand USD | 275.81% |
| Integrative Health Technologies, Inc. | 38.68 Thousand USD | 3744.447% |
| InVitro International | 1553.00 USD | 90892.015% |
| Lumos Diagnostics Holdings Limited | -8.59 Million USD | 83.589% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | -2326.349% |
| Medical Imaging Corp. | -3.02 Million USD | 53.358% |
| NovelStem International Corp. | -4.18 Million USD | 66.327% |
| Optigenex Inc. | -2.89 Million USD | 51.342% |
| PharmChem, Inc. | 845.1 Thousand USD | 266.844% |
| Proteome Sciences plc | -2.44 Million USD | 42.284% |
| Response Genetics, Inc | -20.18 Million USD | 93.014% |
| Rennova Health, Inc. | -3.29 Million USD | 57.183% |
| RushNet, Inc. | -607.02 Thousand USD | -132.279% |
| ScreenPro Security Inc. | -2.24 Million USD | 37.299% |
| Stella Diagnostics Inc. | -5.7 Million USD | 75.295% |
| StageZero Life Sciences Ltd. | -11.41 Million USD | 87.648% |
| Todos Medical Ltd. | -24.99 Million USD | 94.359% |